Text Size

Remicade Safety Line (Study P03236)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Schering-Plough
ClinicalTrials.gov Identifier:
NCT00748826
First received: September 5, 2008
Last updated: December 22, 2011
Last verified: December 2011
History of Changes
Results First Received: December 22, 2011  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Condition: Arthritis, Rheumatoid
Intervention: Biological: Infliximab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
508 rheumatoid arthritis participants initially enrolled on study. An additional 68 participants with psoriatic arthritis (PsA) were enrolled but were not included in the analyses.

Reporting Groups
  Description
Infliximab Patients with active rheumatoid arthritis (RA) confirmed with ACR criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of Infliximab therapy with additional infusions of 5 mg/kg at week 2

Participant Flow:   Overall Study
    Infliximab  
STARTED     508 [1]
COMPLETED     207  
NOT COMPLETED     301  
[1] Of 576 total enrolled, 68 out of scope participants were not used for analyses



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Infliximab Patients with active rheumatoid arthritis (RA) confirmed with ACR criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of Infliximab therapy with additional infusions of 5 mg/kg at week 2

Baseline Measures
    Infliximab  
Number of Participants  
[units: participants]
 		  508  
Age  
[units: years]
Mean ± Standard Deviation 		  52.80  ± 13.56  
Gender  
[units: participants]
 		 
Female     357  
Male     151  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants Who Had the Mendel Mantoux Test as the First Screening Test for Active or Latent Tuberculosis (TB) Before Starting Treatment   [ Time Frame: Baseline ]
  Show Outcome Measure 1

2.  Primary:   Number of Participants Who Had the Tine Test as the First Screening Test for Active or Latent Tuberculosis Before Starting Treatment   [ Time Frame: Baseline ]
  Show Outcome Measure 2

3.  Primary:   Number of Participants Who Had the In-vitro TB Test as the First Screening Test for Active or Latent Tuberculosis Before Starting Treatment   [ Time Frame: Baseline ]
  Show Outcome Measure 3

4.  Primary:   Number of Participants Who Had a Chest X-ray as Part of TB Screening for Active or Latent Tuberculosis Before Starting Treatment   [ Time Frame: Baseline ]
  Show Outcome Measure 4


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Vice President, Late Stage Development Group Leader
Organization: Merck Sharp & Dome Corp
e-mail: ClinicalTrialsDisclosure@merck.com


No publications provided


Responsible Party: Schering-Plough
ClinicalTrials.gov Identifier: NCT00748826     History of Changes
Other Study ID Numbers: P03236
Study First Received: September 5, 2008
Results First Received: December 22, 2011
Last Updated: December 22, 2011
Health Authority: Germany: Paul-Ehrlich-Institut